Gefitinib: all 239 studies that test it

Page 3 of 3. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast CancerCompletedNCT00077025Phase 2
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
• Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00071994Phase 2
• Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung CancerCompletedNCT00068653Phase 2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast CancerCompletedNCT00066378Phase 2
• Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor TherapyCompletedNCT00066339Phase 2
• Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung CancerCompletedNCT00062270Phase 1/2
• This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.CompletedNCT00059722Phase 2
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial SarcomaCompletedNCT00052754Phase 2
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal CancerTerminatedNCT00052585Phase 2
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeCompletedNCT00052208Phase 1/2
• Gefitinib in Treating Patients With Cervical CancerCompletedNCT00049556Phase 2
• Iressa/Docetaxel in Non-Small-Cell Lung CancerWithdrawnNCT00048087Phase 2
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder CancerCompletedNCT00041106Phase 2
• Gefitinib in Treating Children With Refractory Solid TumorsCompletedNCT00040781Phase 1
• Gefitinib and Capecitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00039390Phase 1
• Iressa Expanded Access Program (EAP)CompletedNCT00034879Phase 3
• Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck CancerTerminatedNCT00033449Phase 1
• ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal CancerCompletedNCT00030524Phase 2
• Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00029003Phase 2
• Gefitinib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT00027690Phase 2
• Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary GliomaCompletedNCT00027625Phase 1
• Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerCompletedNCT00026299Phase 1/2
• Gefitinib in Treating Patients With Recurrent or Progressive CNS TumorsCompletedNCT00025675Phase 2
• Gefitinib in Treating Patients With Recurrent Metastatic Colorectal CancerCompletedNCT00025350Phase 2
• Gefitinib in Treating Patients With Malignant MesotheliomaCompletedNCT00025207Phase 2
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal CancerCompletedNCT00025142Phase 2
• ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00025116Phase 2
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerCompletedNCT00024154Phase 2
• Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00024089Phase 2
• Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00023699Phase 2
• Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryCompletedNCT00020709Phase 3
• ZD 1839 in Treating Patients With Glioblastoma Multiforme in First RelapseCompletedNCT00016991Phase 2
• ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and NeckCompletedNCT00015964Phase 2
• ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney CancerCompletedNCT00014183Phase 2
• Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00014170Phase 2
• S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00014144Phase 2
• ZD 1839 in Treating Patients With Metastatic Kidney CancerCompletedNCT00012337Phase 2

← Gefitinib overview